Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology

Hepatology Research

Volumn 46, Issue 1, 2016, Pages 50-57

  Chiba, Tetsuhiro ^a   Iwama, Atsushi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cancer stem cell; Hepatocellular carcinoma; Polycomb group gene product; Stem cell biology; Tumor initiating cell

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; DISULFIRAM; EPITHELIAL CELL ADHESION MOLECULE; ISOCITRATE DEHYDROGENASE; METFORMIN; MICRORNA; PTC 209; SAL LIKE PROTEIN 4; SALAZOSULFAPYRIDINE; THY 1 ANTIGEN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ZEBULARINE; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SELF-RENEWAL; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; EPIGENETICS; EXOME; GENE; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; MACROPHAGE; NONHUMAN; PATHOGENESIS; PCG GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84959304460     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12548     Document Type: Review

References (75)

1. Valent P, Bonnet D, De Maria R, etal. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12: 767-75.
2. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12: 133-43.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
4. Hirschmann-Jax C, Foster AE, Wulf GG, etal. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101: 14228-33.
5. Chiba T, Kita K, Zheng YW, etal. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-51.
6. Ginestier C, Hur MH, Charafe-Jauffret E, etal. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
7. Dollé L, Best J, Empsen C, etal. Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naïve mice. Hepatology 2012; 55: 540-52.
8. Ma S, Chan KW, Lee TK, etal. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-53.
9. Muramatsu S, Tanaka S, Mogushi K, etal. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology 2013; 58: 218-28.
10. Suetsugu A, Nagaki M, Aoki H, etal. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-4.
11. Yang W, Yan HX, Chen L, etal. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287-95.
12. Yang ZF, Ngai P, Ho DW, etal. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-28.
13. Yamashita T, Ji J, Budhu A, etal. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
14. Zhu Z, Hao X, Yan M, etal. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-78.
15. Haraguchi N, Ishii H, Mimori K, etal. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-39.
16. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
17. Lee TK, Cheung VC, Lu P, etal. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014; 60: 179-91.
18. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
19. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275-91.
20. Gerlinger M, Rowan AJ, Horswell S, etal. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
21. Yachida S, Jones S, Bozic I, etal. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
22. Yamashita T, Honda M, Nakamoto Y, etal. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484-97.
23. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
24. Yamashita T, Forgues M, Wang W, etal. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.
25. Chiba T, Zheng YW, Kita K, etal. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007; 133: 937-50.
26. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
27. Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett 2009; 286: 145-53.
28. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118: 409-18.
29. Konuma T, Oguro H, Iwama A. Role of the polycomb group proteins in hematopoietic stem cells. Dev Growth Differ 2010; 52: 505-16.
30. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
31. Chiba T, Miyagi S, Saraya A, etal. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008; 68: 7742-9.
32. Aoki R, Chiba T, Miyagi S, etal. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol 2010; 52: 854-63.
33. Chiba T, Suzuki E, Negishi M, etal. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-67.
34. Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. Proc Natl Acad Sci U S A 2006; 103: 16319-24.
35. Oikawa T, Kamiya A, Kakinuma S, etal. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology 2009; 136: 1000-11.
36. Oikawa T, Kamiya A, Zeniya M, etal. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013; 57: 1469-83.
37. Yong KJ, Gao C, Lim JS, etal. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; 368: 2266-76.
38. Zeng SS, Yamashita T, Kondo M, etal. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 2014; 60: 127-34.
39. Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014; 38: 966-72.
40. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
41. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
42. Chiba T, Saito T, Yuki K, etal. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 2015; 136: 289-98.
43. Kondo Y, Shen L, Suzuki S, etal. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007; 37: 974-83.
44. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med 2011; 17: 291-3.
45. Saha SK, Parachoniak CA, Ghanta KS, etal. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2014; 513: 110-4.
46. Ji J, Yamashita T, Budhu A, etal. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
47. Ma S, Tang KH, Chan YP, etal. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
48. Trumpp A, Wiestler OD. Mechanisms of Disease: cancer stem cells--targeting the evil twin. Nat Clin Pract Oncol 2008; 5: 337-47.
49. Kreso A, van Galen P, Pedley NM, etal. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014; 20: 29-36.
50. Suvà ML, Riggi N, Janiszewska M, etal. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-8.
51. Xu B, On DM, Ma A, etal. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015; 125: 346-57.
52. McCabe MT, Ott HM, Ganji G, etal. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-12.
53. Marquardt JU, Thorgeirsson SS. SnapShot: Hepatocellular carcinoma. Cancer Cell 2014; 25: 550.e1.
54. Raggi C, Factor VM, Seo D, etal. Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology 2014; 59: 2251-62.
55. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 2009; 1: 12-25.
56. Ogawa K, Tanaka S, Matsumura S, etal. EpCAM-targeted therapy for human hepatocellular carcinoma. Ann Surg Oncol 2014; 21: 1314-22.
57. Smith LM, Nesterova A, Ryan MC, etal. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99: 100-9.
58. Yin C, Lin Y, Zhang X, etal. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 2008; 48: 1528-39.
59. Yamashita T, Honda M, Nio K, etal. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 2010; 70: 4687-97.
60. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-6.
61. Wilhelm SM, Carter C, Tang L, etal. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
62. Yi L, Xiao H, Xu M, etal. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 2011; 232: 75-82.
63. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
64. Jalving M, Gietema JA, Lefrandt JD, etal. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-80.
65. Saito T, Chiba T, Yuki K, etal. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One 2013; 8: e70010.
66. Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology 2013; 58: 810-8.
67. Zhou J, Wulfkuhle J, Zhang H, etal. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007; 104: 16158-63.
68. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used antialcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2009; 66: 10425-33.
69. Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets 2011; 11: 332-7.
70. Yip NC, Fombon IS, Liu P, etal. Disulfiram modulated ROS-MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 2011; 104: 1564-74.
71. Chiba T, Suzuki E, Yuki K, etal. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS One 2014; 9: e84807.
72. Liu P, Brown S, Goktug T, etal. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 2012; 107: 1488-97.
73. Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am 1992; 21: 643-58.
74. Yoshikawa M, Tsuchihashi K, Ishimoto T, etal. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1855-66.
75. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000; 32: 78-84.